<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 2)*
Pharmhouse Corp.
(Name of Issuer)
Common Stock, $.01 par value
(Title of Class of Securities)
717137103
(CUSIP Number)
Stanley Pollack, Esq. at Rosenthal & Rosenthal, Inc., 1370 Broadway, New York,
New York 10018 (212) 356-1441
(Name, Address and Telephone Number of Person Authorized to Receive Notices and
Communications)
July 16, 1997
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13-1(b)(3) or (4), check the following box / /.
NOTE: Six copies of this statement, including all exhibits, should be filed with
the Commission. See Rule 13d-1(a) for other parties to whom copies are to be
sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
<PAGE> 2
SCHEDULE 13D
- ------------------- ------------------
CUSIP NO. 717137103 PAGE 2 OF 18 PAGES
- ------------------- ------------------
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Rosenthal & Rosenthal, Inc.
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) / /
(b) / /
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
N/A
- --------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) or 2(e) / /
- --------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
New York
- --------------------------------------------------------------------------------
7 SOLE VOTING POWER
-0-
NUMBER OF -------------------------------------------------------
SHARES 8 SHARED VOTING POWER
BENEFICIALLY -0-
OWNED BY -------------------------------------------------------
EACH 9 SOLE DISPOSITIVE POWER
REPORTING -0-
PERSON -------------------------------------------------------
WITH 10 SHARED DISPOSITIVE POWER
-0-
- --------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
- 0 -
- --------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
/ /
- 0 -
- --------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
- 0 -
- --------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
CO
- --------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE> 3
SCHEDULE 13D
- ------------------- ------------------
CUSIP NO. 717137103 PAGE 3 OF 18 PAGES
- ------------------- ------------------
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Rosenthal, Inc.
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) / /
(b) / /
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
N/A
- --------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) or 2(e) / /
- --------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
- --------------------------------------------------------------------------------
7 SOLE VOTING POWER
-0-
NUMBER OF -------------------------------------------------------
SHARES 8 SHARED VOTING POWER
BENEFICIALLY -0-
OWNED BY -------------------------------------------------------
EACH 9 SOLE DISPOSITIVE POWER
REPORTING -0-
PERSON -------------------------------------------------------
WITH 10 SHARED DISPOSITIVE POWER
-0-
- --------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
- 0 -
- --------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
/ /
- 0 -
- --------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
- 0 -
- --------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
CO
- --------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE> 4
AMENDMENT NO. 2 TO SCHEDULE 13D
This Amendment No. 2 dated July 22, 1997 to Schedule 13D amends the
Schedule 13D relating to shares of Common Stock, par value $.01 per share (the
"Shares"), of Pharmhouse Corp. (formerly known as S.E. Nichols Inc.) filed with
the Securities and Exchange Commission in January 1992 by Rosenthal &
Rosenthal, Inc., a New York corporation ("R&R"), as amended by Amendment No. 1
dated June 30, 1997 (the "Initial Schedule 13D"). The purpose of filing this
Amendment is to reflect the change since the most recent filing that R&R has
sold all of the Shares it beneficially owned and is no longer the beneficial
owner of more than 5% of such Shares. Capitalized terms used and not defined
herein shall have the meanings ascribed to them in the Initial Schedule 13D.
ITEM 2. IDENTITY AND BACKGROUND
Item 2 is hereby amended by deleting the phrase "Exhibit 7" at the end
of the first paragraph and substituting therefor the phrase "Exhibit 8."
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER
Item 5 is hereby amended in its entirety to read as follows:
(a) and (b) See (c) below. R&R and the Parent no longer beneficially
own any Shares.
(c) On July 16, 1997, R&R sold, of the 209,195 Shares it beneficially
owned, 190,000 Shares at a price per share of $6.00 and 2,400 Shares at a price
per share of $6.75 on the NASDAQ Small Cap Market, thereby reducing the
percentage of Shares beneficially owned by R&R from 8.1% to below 5%. R&R sold
16,795 Shares in the aggregate, the amount of which equals the remainder of the
209,195 Shares owned by R&R, on July 11, 14, 15 and 17, 1997 on the NASDAQ
Small Cap Market, thereby reducing the percentage of Shares beneficially owned
by R&R to 0%.
(d) None.
(e) July 16, 1997.
ITEM 7. MATERIAL TO BE FILED AS EXHIBITS
Item 7 is hereby amended by adding the following at the end thereof:
Exhibit 8 - Joint Filing Agreement dated as of July 22, 1997 by and
between R&R and the Parent.
4
<PAGE> 5
SIGNATURES
After reasonable inquiry and to the best of each of the undersigned's
knowledge and belief, each of the undersigned hereby certifies that the
information set forth in this statement is true, complete and correct.
Dated: July 22, 1997
ROSENTHAL & ROSENTHAL, INC.
By /s/ Stanley Pollack
--------------------------------------
Name: Stanley Pollack
Title: Senior Executive Vice President
ROSENTHAL, INC.
By /s/ Stanley Pollack
--------------------------------------
Name: Stanley Pollack
Title: Executive Vice President
5
<PAGE> 6
EXHIBIT INDEX
Exhibit 8 - Joint Filing Agreement dated as of July 22, 1997 by and between
R&R and the Parent.
<PAGE> 1
EXHIBIT 8
JOINT FILING AGREEMENT
The undersigned hereby agree to file jointly Amendment No. 2 to the
Statement on Schedule 13D (the "Statement") relating to the Common Stock, $.01
par value per share, of Pharmhouse Corp. (formerly known as S.E. Nichols Inc.)
and any further amendments thereto which may be deemed necessary pursuant to
Regulation 13D or G promulgated under Section 13 of the Securities Exchange Act
of 1934, as amended.
It is understood and agreed that a copy of this Agreement shall be
attached as an exhibit to the Statement, filed on behalf of each of the parties
hereto.
This Agreement may be executed in multiple counterparts, each of which
shall constitute an original, one and the same instrument.
IN WITNESS WHEREOF, each of the undersigned has executed this Agreement
as of July 22, 1997.
ROSENTHAL & ROSENTHAL, INC.
By /s/ Stanley Pollack
--------------------------------------
Name: Stanley Pollack
Title: Senior Executive Vice President
ROSENTHAL, INC.
By /s/ Stanley Pollack
--------------------------------------
Name: Stanley Pollack
Title: Executive Vice President
11
